The mass offshoring of a high-innovation sector in which the United States has been a global leader for decades has been happening with the knowledge and approval of pharmaceutical executives looking to make short-term profits. Naturally, it would have disastrous consequences for the United States. Beyond the national security concerns associated with losing biotech to a peer strategic adversary, biotech has become a valuable industry that provi…